Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 1.18
CORT's Cash to Debt is ranked lower than
77% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: 61.94 vs. CORT: 1.18 )
Ranked among companies with meaningful Cash to Debt only.
CORT' s 10-Year Cash to Debt Range
Min: 0.72  Med: 1167.49 Max: No Debt
Current: 1.18
Equity to Asset 0.24
CORT's Equity to Asset is ranked lower than
87% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. CORT: 0.24 )
Ranked among companies with meaningful Equity to Asset only.
CORT' s 10-Year Equity to Asset Range
Min: -0.1  Med: 0.63 Max: 0.89
Current: 0.24
-0.1
0.89
F-Score: 3
Z-Score: 0.13
M-Score: -2.12
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -34.88
CORT's Operating margin (%) is ranked higher than
57% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -71.14 vs. CORT: -34.88 )
Ranked among companies with meaningful Operating margin (%) only.
CORT' s 10-Year Operating margin (%) Range
Min: -69827.59  Med: -2540.46 Max: -104.02
Current: -34.88
-69827.59
-104.02
Net-margin (%) -43.46
CORT's Net-margin (%) is ranked higher than
54% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -67.10 vs. CORT: -43.46 )
Ranked among companies with meaningful Net-margin (%) only.
CORT' s 10-Year Net-margin (%) Range
Min: -69537.93  Med: -2401.04 Max: -118.2
Current: -43.46
-69537.93
-118.2
ROE (%) -399.78
CORT's ROE (%) is ranked lower than
96% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. CORT: -399.78 )
Ranked among companies with meaningful ROE (%) only.
CORT' s 10-Year ROE (%) Range
Min: -8507.59  Med: -117.64 Max: -55.4
Current: -399.78
-8507.59
-55.4
ROA (%) -39.17
CORT's ROA (%) is ranked lower than
61% of the 866 Companies
in the Global Biotechnology industry.

( Industry Median: -27.09 vs. CORT: -39.17 )
Ranked among companies with meaningful ROA (%) only.
CORT' s 10-Year ROA (%) Range
Min: -124.18  Med: -80.36 Max: -51.57
Current: -39.17
-124.18
-51.57
ROC (Joel Greenblatt) (%) -792.32
CORT's ROC (Joel Greenblatt) (%) is ranked lower than
58% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -390.34 vs. CORT: -792.32 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CORT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -391957.14  Med: -69112.91 Max: -2412.14
Current: -792.32
-391957.14
-2412.14
EBITDA Growth (3Y)(%) -11.50
CORT's EBITDA Growth (3Y)(%) is ranked lower than
60% of the 429 Companies
in the Global Biotechnology industry.

( Industry Median: -4.70 vs. CORT: -11.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CORT' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: -11.50 Max: 3.6
Current: -11.5
0
3.6
EPS Growth (3Y)(%) -7.40
CORT's EPS Growth (3Y)(%) is ranked lower than
51% of the 418 Companies
in the Global Biotechnology industry.

( Industry Median: -6.80 vs. CORT: -7.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CORT' s 10-Year EPS Growth (3Y)(%) Range
Min: -31.3  Med: -7.40 Max: 6.6
Current: -7.4
-31.3
6.6
» CORT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

CORT Guru Trades in Q4 2013

Steven Cohen Sold Out
First Eagle Investment 991,978 sh (-60.26%)
» More
Q1 2014

CORT Guru Trades in Q1 2014

Steven Cohen 14,329 sh (New)
First Eagle Investment Sold Out
» More
Q1 2015

CORT Guru Trades in Q1 2015

Jim Simons 55,400 sh (New)
» More
Q2 2015

CORT Guru Trades in Q2 2015

First Eagle Investment 200,000 sh (New)
Jim Simons 501,614 sh (+805.44%)
» More
» Details

Insider Trades

Latest Guru Trades with CORT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 44.66
CORT's P/B is ranked lower than
98% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. CORT: 44.66 )
Ranked among companies with meaningful P/B only.
CORT' s 10-Year P/B Range
Min: 1.26  Med: 5.33 Max: 97.67
Current: 44.66
1.26
97.67
P/S 13.19
CORT's P/S is ranked lower than
56% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 10.47 vs. CORT: 13.19 )
Ranked among companies with meaningful P/S only.
CORT' s 10-Year P/S Range
Min: 10.69  Med: 152.00 Max: 615
Current: 13.19
10.69
615
Current Ratio 2.56
CORT's Current Ratio is ranked lower than
67% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.14 vs. CORT: 2.56 )
Ranked among companies with meaningful Current Ratio only.
CORT' s 10-Year Current Ratio Range
Min: 2.22  Med: 7.90 Max: 37.77
Current: 2.56
2.22
37.77
Quick Ratio 2.48
CORT's Quick Ratio is ranked lower than
65% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. CORT: 2.48 )
Ranked among companies with meaningful Quick Ratio only.
CORT' s 10-Year Quick Ratio Range
Min: 2.14  Med: 7.90 Max: 37.77
Current: 2.48
2.14
37.77
Days Inventory 362.04
CORT's Days Inventory is ranked lower than
89% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 122.55 vs. CORT: 362.04 )
Ranked among companies with meaningful Days Inventory only.
CORT' s 10-Year Days Inventory Range
Min: 476.53  Med: 1710.69 Max: 2487.36
Current: 362.04
476.53
2487.36
Days Sales Outstanding 47.12
CORT's Days Sales Outstanding is ranked higher than
64% of the 570 Companies
in the Global Biotechnology industry.

( Industry Median: 62.77 vs. CORT: 47.12 )
Ranked among companies with meaningful Days Sales Outstanding only.
CORT' s 10-Year Days Sales Outstanding Range
Min: 45.83  Med: 50.33 Max: 61.48
Current: 47.12
45.83
61.48

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 70.14
CORT's Price/Net Current Asset Value is ranked lower than
95% of the 540 Companies
in the Global Biotechnology industry.

( Industry Median: 6.84 vs. CORT: 70.14 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CORT' s 10-Year Price/Net Current Asset Value Range
Min: 2.43  Med: 5.92 Max: 93.33
Current: 70.14
2.43
93.33
Price/Tangible Book 44.64
CORT's Price/Tangible Book is ranked lower than
97% of the 690 Companies
in the Global Biotechnology industry.

( Industry Median: 5.33 vs. CORT: 44.64 )
Ranked among companies with meaningful Price/Tangible Book only.
CORT' s 10-Year Price/Tangible Book Range
Min: 2.31  Med: 5.81 Max: 93.33
Current: 44.64
2.31
93.33
Price/Median PS Value 0.09
CORT's Price/Median PS Value is ranked higher than
98% of the 542 Companies
in the Global Biotechnology industry.

( Industry Median: 1.07 vs. CORT: 0.09 )
Ranked among companies with meaningful Price/Median PS Value only.
CORT' s 10-Year Price/Median PS Value Range
Min: 0.08  Med: 0.31 Max: 3.44
Current: 0.09
0.08
3.44
Earnings Yield (Greenblatt) (%) -2.50
CORT's Earnings Yield (Greenblatt) (%) is ranked higher than
64% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -6.10 vs. CORT: -2.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CORT' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -11  Med: 3588.90 Max: 3588.9
Current: -2.5
-11
3588.9

Analyst Estimate

Dec15
Revenue(Mil) 46
EPS($) -0.22
EPS without NRI($) -0.22

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:HTD.Germany,
Corcept Therapeutics Inc was incorporated in the State of Delaware on May 13, 1998. The Company is a pharmaceutical Company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic and psychiatric and oncologic disorders. Company focuses on disorders associated with the steroid hormone cortisol. The company focuses on commercializing Korlym 300 mg Tablet, a once-daily oral medication for treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushings syndrome, who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It is also conducting a Phase III clinical study for mifepristone, the active ingredient in Korlym, for the treatment of psychotic depression; and developing CORT 108297, a novel glucocorticoid receptor II antagonist in Phase 1b/2a clinical trial. The Company has research and development agreement with Argenta Discovery Limited; Sygnature Discovery Limited; ICON Clinical Research, L.P.; and MedAvante, Inc. as well as has a patent license from Stanford University for developing mifepristone.
» More Articles for CORT

Headlines

Articles On GuruFocus.com
Corcept Therapeutics to Announce Second Quarter Financial Results and Corporate Update and Host Conf Jul 29 2015 
Two Stocks for the Value Investor and GAARP Enthusiast Jun 07 2014 
Corcept Therapeutics Inc. Reports Operating Results (10-K/A) Aug 19 2010 
Corcept Therapeutics Inc. Reports Operating Results (10-Q) Aug 16 2010 
Corcept Therapeutics Inc. Reports Operating Results (10-Q) Nov 12 2009 
Corcept Therapeutics Inc. Reports Operating Results (10-Q) Aug 11 2009 
Corcept Therapeutics Inc. Reports Operating Results (10-Q) May 13 2009 

More From Other Websites
CORCEPT THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers Sep 03 2015
Novartis (NVS) Launches Zarxio: First Biosimilar in the U.S. Sep 03 2015
Juniper Pharmaceuticals (JNP) Rises: Stock Jumps 5.6% Sep 03 2015
Collegium Pharmaceutical (COLL) in Focus: Stock Tumbles 14% Sep 02 2015
Bristol-Myers to Pay up to $1.25B for Right to Buy Promedior Sep 01 2015
New Strong Buy Stocks for September 1st Sep 01 2015
Cortendo Announces Filing of Registration Statement for Proposed Initial Public Offering Aug 31 2015
Sucampo to Acquire R-Tech Ueno for About $278 Million Aug 27 2015
Corcept Therapeutics (CORT) Jumps: Stock Moves Up 10.9% Aug 27 2015
CORCEPT THERAPEUTICS INC Financials Aug 18 2015
Corcept Therapeutics (CORT): An Off-the-Radar Potential Winner Aug 14 2015
Immune Design's Q2 Loss Narrows Y/Y, Focus on Pipeline Aug 13 2015
10-Q for Corcept Therapeutics, Inc. Aug 09 2015
CORCEPT THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report Aug 07 2015
Corcept's Q2 Loss Narrower than Expected, View Narrowed - Analyst Blog Aug 06 2015
Edited Transcript of CORT earnings conference call or presentation 5-Aug-15 9:00pm GMT Aug 05 2015
Corcept Therapeutics Announces Second Quarter 2015 Results and Provides Corporate Update Aug 05 2015
CORCEPT THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure Aug 05 2015
Corcept Therapeutics Announces Second Quarter 2015 Results and Provides Corporate Update Aug 05 2015
Q2 2015 Corcept Therapeutics Inc Earnings Release - After Market Close Aug 05 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK